Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

December 31, 2004

Study Completion Date

October 31, 2009

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

autologous neuroblastoma vaccine

A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.

Trial Locations (1)

77030

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Malcolm Brenner

OTHER